These results are consistent with the previous findings that depletion of BMAL1 sensitized breast cancer cells to cisplatin and doxorubicin [56] and suggest that BMAL1 may have potential as a therapeutic target, because its inhibition or depletion could improve cancer treatment outcomes. This evidence concerns the gene BMAL1 and cancer.